tag:blogger.com,1999:blog-308374462024-03-13T08:28:03.372-07:00Neurology MinutiaeArcane items of medical obscurity are the neurologist's lifeblood. We can figure stuff out. This blogger is interested in diseases that affect people-- go somewhere else for results of rat research. Information is meant to be advanced but clinically relevant esoterica.Unknownnoreply@blogger.comBlogger421125tag:blogger.com,1999:blog-30837446.post-4006631497227436092023-10-10T06:37:00.001-07:002023-10-10T06:37:19.433-07:00Migraine pearls
The Wand at drinkpure wine.com eliminiates sulfites in wine for people sensitive to wine headaches.
Celtic Sea Salt instead of table salt"takes water into cells" to promote hydration, lowers BP and helps headaches.Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-84851846844749542022022-07-31T07:03:00.001-07:002022-07-31T07:03:16.665-07:00Pearls Chiari malformation1.80 percent of patients with cough headache have cm type 1 although only a minority of patients with cm 1 have cough headache. The degree of tonsillar herniation does not correlate<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script><div><br /></div><div>2. Cm1 presents most often from ages 8 to 9 and from 31 to 46</div><div><br /></div><div>3. Spinal cord syndrome occurs in 65 to 84 percent and includes weakness and sensory changes.</div><div><br /></div><div>4. Brain stem syndrome occurs in 22 to 38 percent and includes blurred vision, horizontal or downbeating nystagmus, and diplopia (upper) or hoarseness , dysphonia, dysarthria, dysphasia, vocal cord paralysis, palatal weakness and tongue atrophy ( lower).</div><div><br /></div><div>5. Cerebella symptoms occur in 11 percent with dyscoordination, ataxia and dysmetria</div><div><br /></div><div>6. Cortical symptom is rare 3 percent with brain fog, depression, generalized weakness and fatigue</div><div><br /></div><div>7. Even more rare systemic syndrome , two percent, have chest pain, sob, postural hypotension and syncope</div><div><br /></div><div>8 presenting symptoms include 82 to 90 percent have suboccipital headache, 78 to 81 percent have posterior neck pain, 60 to 67 have dizziness, 49 percent have nausea.</div><div><br /></div><div>Others with percent</div><div>Weakness. 69</div><div>Numbness 56</div><div>Altered temperature sensation 52</div><div>Unsteady 40</div><div>Double vision 13</div><div>Swallowing trouble 8</div><div>Tinnitus. 7</div><div>Dysarthria 3</div><div>Dizzy. 3</div><div>Hiccups. 1</div><div><br /></div><div>9. Ciné mri phase contrast may show elevated high velocity jets upwards and other abnormalities of normal bidirectional csf flow. Technique also can be used to follow cm1. Technique is especially useful to differentiate headaches of cm1 v other causes</div>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-55500927245802504802020-11-22T14:59:00.000-08:002020-11-22T14:59:58.472-08:00Luna G, Alping P, Burman J et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximabm and injectable therapies. JAMA Neurology2020; 77:184-91.<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script><script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script><div><br /></div><div>Swedish study examines risk of infections severe enough to cause hospitalization in 6421 MS patients and controls. The rate of infections among patients taking injectibles was higher than the population 8.9 v 5.2 per 1000 person years. It was higher still in patients taking fingoli,od (14.3), and natalizumab (11.4) and highest among patients taking rituximab (19.7).</div>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-69565383483062438642020-11-22T14:35:00.000-08:002020-11-22T14:35:24.315-08:00MG after dabrafenib and trametinib in metastatic melanoma. Case report. Neurology 2020; 94: 322-3/<div><br /></div><div>In this patient, challenge , withdraw and rechallenge brought out MG symptoms and resolved when withdrawn within 24 hours. {atient was ab positive. These drugs, BRAF and MEK inhibitors now are standard of care for melanoma. This is a separate phenomenon from checkpoint inhibitors causing mg <script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script><script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-68946099515994557532020-11-22T14:23:00.001-08:002020-11-22T14:23:25.518-08:00A Columbian woman in a kindred of patients who developed Alzheimer's disease was homozygote for the Christchurch mutation, which is rare, and maintained cognition into her seventies. She was apo E3 double positive. She had high amyloid but limited tau. This provides a potential target for studies.Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-34159065921675368932020-11-22T14:12:00.000-08:002020-11-22T14:12:59.551-08:00Atrial fibrillation and falls: a mechanistic or age confounded relationship? (editorial) Mayo Clinic Proceedings 95; 2020, pp632-4 AuthorsHu T et al. <script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script><div><br /></div><div><br /></div><div><br /></div><div>Meta-analysis shows falls and AF are related, independently of age. Odds ratio is about 1.8. The relationship exists even after pacemaker placement. Authors cite an AF complex of symptoms that include cognitive dysfunction, endothelial dysfunction and dysautonomia. </div>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-19157487452606232422019-11-13T13:15:00.001-08:002019-11-13T13:15:36.109-08:00Dermatomyositis with and without anti Mi2 autoantibodies<div dir="ltr" style="text-align: left;" trbidi="on">
Pinal-Hernandez I, Mecoli CA, Casal-Dominguez M<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script> . More prominent muscle involvement with dermatomyositis with anti Mi2 autoantibodies. Neurology; 2019; 93e1768-1777<br />
(John Hopkins)<br />
<br />
58 patients with antiMi2 positive DM<br />
143 patient with anti Mi2 negative DM<br />
162 patients with antisynthetase syndrome<br />
170 patients with immune mediated necrotizing myopathy (IMNM). <br />
<br />Features of <span style="-webkit-text-stroke-width: 0px; background-color: transparent; color: black; display: inline !important; float: none; font-family: Times New Roman; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">patients with antiMi2 positive DM: more muscle weakness, less calcinosis , less interstitial lung disease, higher CK level but still stronger with lower CK's than pats with IMNM</span><br /><script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-49148628801319972162017-02-07T13:56:00.000-08:002017-02-07T13:56:36.700-08:00Autoimmune meningoencephalitis associated with GFAP IgG antibodies.<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script>Fung B et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 2016; 73: 1297.<br />
<br />
Mayo labs has 134 cases out of 100,000 evaluated for autoimmune and paraneoplastic ab's as part of routine care. Clinical presentation consists of headache, confusion, behavioral changes, lethargy, blurred vision, and trouble walking. Exam can show papillitis, CN palsies, myelopathy. CSF can show pleocytosis, highprotein, OCB'sm high IgG index. MRI can show leptomeningeal enhancement, gyral enhancement. At least half relapsed despite corticosteroids. 6/16 developed cancers</div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-69798871498062890442017-02-07T13:43:00.003-08:002017-02-07T13:43:50.156-08:00Steroid sparing therapy in neurosarcoidosis<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script>Neurology 2016; 13:87:2517 Uncontrolled study of 40 patients with neurosarcoidosis, both central and peripheral nerve. 32 got MTX 20 mg per week, 14 got mycophenolate (MMF) at 2 grams per day (median) 6 had both drugs successively. In MTX group, 15/32 (46 percent) relapsed v. 11/14 (79 %) in MMF group. Median survival without relapse was 28 months in MTX group, 11 month in MMF group. Of note steroid dose at initiation was 40 mg po daily in MTX group, and 20 mg in MMF group, a potential confound. Both groups had high rates of relapse and better steroid sparing drugs are needed. </div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-972253279207076772016-11-29T17:20:00.003-08:002016-11-29T17:20:49.432-08:00Biotinidase deficiency mimicking NMO: initiallyexhibiting symptoms in adulthood<div dir="ltr" style="text-align: left;" trbidi="on">
Bottin L, Prud'honS, Giannesini C et al. Multiple Sclerosis 21 (12) 1604-07 2015. <script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script>
<div>
<br /></div>
<div>
Authors present first case of biotinidase deficiency presenting in young adulthood ; children and adolescents may present with vision loss and tetraparesis. It was due in this case to a novel missense mutation and partly improved with oral biotin therapy.</div>
</div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-21962788800696076152016-11-08T08:35:00.001-08:002016-11-08T08:35:19.003-08:00Seropositive voltage gated calcium channels, utility<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script><br />
<div dir="ltr" style="text-align: left;" trbidi="on">
Jammoul A, Shayya L, Mente K
et al. Neurology Clinical Practice 2016; 6:409-418.<br /><br />Authors
differentiate "classic" group with limbic encephalitis or neuromyotonia (9.6% of
total) and note the others had a panoply of diagnoses that were nonclassic. The
classic group was more likely to have high titers of ab, but there was overlap.
91 % of lcassic and 21 % of nonclassic had levels > 0.25 nM. 75 % of
patietns in high level ab group had autoimmune disorders, and 75 % of patients
with low level titers did not. 26 % of patients had a remote malignancy
(active, remote, solid or hematologic) but not ab titer difference was noted
among the groups .<br /><br />Conclusions: 1. High VGKC ab levels are found in
patients with classic and other autoimmune disorderes, Low level ab titers are
seen in nonspecific and mostly nonautoimmune disorders<br /><br />2. The presence
of VGKC antibodies rather than the level may serve as a marker of
malignancy<br /><br />Notes this is bad on a chart review of 6,032 patients who
underwent evaluation .<br /><br />The nonclassic group includes PNS and CNS
diorders including neuropathy, dementia, ALS, CJD. Some patietns had
nonspecific symptoms such as stutering speech, nausea and vomting and
orthostasis without diagnosis of neurologic disease.<br /><br />Cancers were
oftendiagnosed due towhole body CT/PET; 2 patietns had previously unknown cancer
(Ovarian and lung). Cancer occurred more commonly in those over age 45. Many
cases of ab finding were remote by over ten years from actual tumor.<br />
</div>
<br /><br /></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-19121905076559496032016-11-08T08:31:00.002-08:002016-11-08T08:31:23.453-08:00Pearls about GQ1b<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script>
<br />
<div>
Serum and CSF GQ1 ab'sin isolated opthalmoplegic syndromes. Spatola M, Du
Pasquier R, Schluep M, et al. Neurology 2016; 86:1780-1784</div>
<br />
<div>
</div>
<br />
<div>
pearls about GQ1b from this article</div>
<br />
<div>
</div>
<br />
<div>
1. Antibodies are specific for Miller Fisher syndrome (MFS); unl;ike
NMO-NMOSD, the use of the antibodies does not increase the spectrum of MFS
substantially</div>
<br />
<div>
</div>
<br />
<div>
2. Measurement in CSF offers no additional value over serum</div>
<br />
<div>
</div>
<br />
<div>
3. Although ON (optic neuritis) can occur as part of the MFS, ISOLATED ON
is NOT part of the MFS spectrum</div>
<br />
<div>
</div>
<br />
<div>
4. In acute opthalmoplegia, only 1/21 had positive antibodies but the
antibodies occurred in 1/5 cases of AO of unknown etiology; therefore, the
antibody may be useful as part of the evaluation of AO. The cases with known
etiology include diabetes, Tolosa Hunt and opsoclonus myoclonus</div>
<br />
<div>
</div>
<br />
<div>
5. Low serum titers occur in several disorders and are markers of
nonspecific damage to ocular motor nerve sheaths, while high concentrations are
specific for MFS</div>
<br />
<div>
</div>
<br />
<div>
6. IgG is the most relevant isotype antibody relevant for MFS, and
GanglioCombi mixed IgM/IgG correlates well which makes it a viable alternative
</div>
</div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-36850335278728863012016-09-27T06:23:00.002-07:002016-09-27T06:23:21.886-07:00code for chronic management labs<div dir="ltr" style="text-align: left;" trbidi="on">
Z79.899<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-75055308051196879422016-06-01T12:27:00.001-07:002016-06-01T12:27:10.903-07:00Froin's syndrome<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script><br />
<div>
CSF showing high protein, xanthochromia and hypercoagulation of CSF is
pathognomonic and it can occur with blockage of CSF by a spinal cord mass or
meningeal irritation from meningitis.</div>
</div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-50955425296690113132016-02-23T11:43:00.001-08:002016-02-23T11:43:19.545-08:00Orthostatic tremor - pearls<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script>Hassan A, Ahlskog AE, Matsumotos JY. Orthostatic tremor: clinical, electrophysiologic and treatment findings in 184 patients. Neurology 2016; 86: 458-464.<br />
<br />
The article is a Mayo series of 184 patients seen over 37 years. <br />
<br />
Definition: lower body tremor activated on standing, absent when seated or lying, improved by walking or leaning. Patients report leg shaking, unsteadiness and imbalance. Electrophysiologic findings are unique: a 13-18 hz tremor of lower limbs or trunk. <br />
<br />
Demographics: 64 percent were female, mean age 59 years, (range 13-88) . One hundred percent reported symptoms only when standing and absent while seated. Descriptions included "imbalance, unsteadiness, weakness, 'funny feeling,' 'jelly legs,' leg tightness, pain, tremor, shakiness, or quivering. Sixty percent of cases included the arms. 24 percent had falls. 28 percent had other types of tremors included ET, which could be associated with a response to alcohol. Other associated tremors included head tremor (1), handwriting tremor (2), functional (1), jaw tremor (1). Forty percent had other neurologic diseases including Parkinson's and many others, degenerative or otherwise. Nine patients had a family history of orthostatic tremor. <br />
<br />
Medication responsiveness occurred in 139 patients. Sixty seven percent of medications prescribed did not demonstrate benefit. The most efficacious was benzodiazepines, especially clonazepam, with 48 percent of patients so treated showing moderate or marked benefit. Thirty three percent of patients given gabapentin showed mild or moderate benefit, with lower responses to valproate, primidone, levodopa (only 1/33 responding), and no benefit from anxiolytics or antidepressants. The responsiveness to clonazepam diminished over time , and of those only a few, 16 got benefit from another drug, including gabapentin, valproic acid, propranolol, pramipexole, bromazepam, primidone, carbi-levodopa, and pregabalin. Three patients underwent DBS and improved.<br />
<br />
There was a high personal anf family history of PD (8.9 and 10.7 percent). <br />
<br />
EMG is easy and pathognomonic. MRI's often show various types of white matter disease and occasional meningiomas.</div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-70685658344077638912016-01-03T17:50:00.002-08:002017-01-30T13:34:35.834-08:00Pellagra and spinal myoclonus<div dir="ltr" style="text-align: left;" trbidi="on">
<span id="role_document" style="color: black; font-family: "arial"; font-size: x-small;">
</span><div>
<span id="role_document" style="color: black; font-family: "arial"; font-size: x-small;"><span id="rolx_document" style="color: black; font-family: "arial"; font-size: x-small;"></span></span><div>
<span id="role_document" style="color: black; font-family: "arial"; font-size: x-small;"><span id="rolx_document" style="color: black; font-family: "arial"; font-size: x-small;">Park K, Oeda T, Sawada H. A case of alcoholic pellegra encephalopathy
presenting with spinal myoclonus. Neurology Clinical Practice 5; 472-3.</span></span></div>
<span id="role_document" style="color: black; font-family: "arial"; font-size: x-small;"><span id="rolx_document" style="color: black; font-family: "arial"; font-size: x-small;">
<div>
</div>
<div>
The authors present a case of alcoholic pellagra with confusion and
myoclonus responding dramatically to administration of niacin1500 mg per day
starting 16 days after admission. Essential points include:</div>
<div>
</div>
<div>
1. Pellagra is rare in US but not in alcoholics</div>
<div>
2. Dermatitis may be subtle and not appreciated</div>
<div>
3. Thiamine and niacin levels may be normal</div>
<div>
4. Thiamine may cause worsening due to increased demand for niacin</div>
<div>
5. Myoclonus in context is important to diagnosis, often stimulus
sensitive</div>
<div>
6. Severe sensory ataxia, incontinence and dysautonomia also occur and
improve with treatment</div>
<div>
</div>
<div>
the 4 D's of pellagra, again, are , diarrhea, dementia, dermatitis and
death<br />
<br />
Additional pearl-- hamsters exposed to niacin deficiency (corn maize diet) cannibalize their young-- cite Current Nature ?</div>
</span><br /></span></div>
<span id="role_document" style="color: black; font-family: "arial"; font-size: x-small;">
</span><br />
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-42517996296970791902016-01-03T17:50:00.000-08:002016-01-03T17:50:17.186-08:00Scurvy and Neurologic disease<div dir="ltr" style="text-align: left;" trbidi="on">
<div>
Meisal K, Daggubati S,Josephson SA. . Scurvy in the 21st century? Vitamin
C deficiency presenting to the neurologist. Neurol Clin Prac 2015;
5:491-493.</div>
<div>
</div>
<div>
Authors present a series of cases with vitamin C deficiency and review some
of the neuro manifestations and non neuro manifestations, ; the former are not
widely known. </div>
<div>
</div>
<div>
Patients with deficiency were caused by various other causes,including
autism, poor status without access to produce, usually rural, were not alcohol
users, had measurable low vitamin C levels. Gingival hyperplasia, rash and
bleeding were non neurologic manifestations. People bruised,especially on their
thighs, Some had other nutritional diseases.. Pain, achiness and weight loss
are expected.</div>
<div>
</div>
<div>
Neuro manifestations included positional tremor, neuralgias100 %), focal
weakness (50 %) including footdrop and scapular winging, normal MRI's, long
tract signs including hyperreflexia and plantar extensors, fatigue, trouble
concentrating, headache, anxiety, and imbalance.</div>
<div>
</div>
<div>
Patients recovered dramatically with treatment.</div>
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-66353686421171514172016-01-03T17:49:00.003-08:002016-01-03T17:49:28.426-08:00Malignant subtypes of Parkinsons<div dir="ltr" style="text-align: left;" trbidi="on">
<div data-sel-dox-entry-content="" id="dox_entry_content">
<b>JAMA Neurology august 2015</b><br />
<b>Importance</b> There is increasing evidence that Parkinson disease
(PD) is heterogeneous in its clinical presentation and prognosis. Defining
subtypes of PD is needed to better understand underlying mechanisms, predict
disease course, and eventually design more efficient personalized management
strategies.<br />
<b>Objectives</b> To identify clinical subtypes of PD, compare the
prognosis and progression rate between PD phenotypes, and compare the ability to
predict prognosis in our subtypes and those from previously published clustering
solutions.<br />
<b>Design, Setting, and Participants</b> Prospective cohort study. The
cohorts were from 2 movement disorders clinics in Montreal, Quebec, Canada
(patients were enrolled during the period from 2005 to 2013). A total of 113
patients with idiopathic PD were enrolled. A comprehensive spectrum of motor and
nonmotor features (motor severity, motor complications, motor subtypes,
quantitative motor tests, autonomic and psychiatric manifestations, olfaction,
color vision, sleep parameters, and neurocognitive testing) were assessed at
baseline. After a mean follow-up time of 4.5 years, 76 patients were reassessed.
In addition to reanalysis of baseline variables, a global composite outcome was
created by merging standardized scores for motor symptoms, motor signs,
cognitive function, and other nonmotor manifestations.<br />
<b>Main Outcomes and Measures</b> Changes in the quintiles of the
global composite outcome and its components were compared between different
subtypes.<br />
<b>Results</b> The best cluster solution found was based on
orthostatic hypotension, mild cognitive impairment, rapid eye movement sleep
behavior disorder (RBD), depression, anxiety, and Unified Parkinson’s Disease
Rating Scale Part II and Part III scores at baseline. Three subtypes were
defined as <i>mainly motor/slow progression</i>, <i>diffuse/malignant</i>, and
<i>intermediate</i>. Despite similar age and disease duration, patients with the
diffuse/malignant phenotype were more likely to have mild cognitive impairment,
orthostatic hypotension, and RBD at baseline, and at prospective follow-up, they
showed a more rapid progression in cognition (odds ratio [OR], 8.7 [95% CI,
4.0-18.7]; <i>P</i> < .001), other nonmotor symptoms (OR, 10.0 [95% CI,
4.3-23.2]; <i>P</i> < .001), motor signs (OR, 4.1 [95% CI, 1.8-9.1];
<i>P</i> = .001), motor symptoms (OR, 2.9 [95% CI, 1.3-6.2]; <i>P</i> < .01),
and the global composite outcome (OR, 8.0 [95% CI, 3.7-17.7];
<i>P</i> < .001).<br />
<b>Conclusions and Relevance</b> It is recommended to screen patients
with PD for mild cognitive impairment, orthostatic hypotension, and RBD even at
baseline visits. These nonmotor features identify a diffuse/malignant subgroup
of patients with PD for whom the most rapid progression rate could be
expected.<br />
<div class="clear">
</div>
</div>
<div class="clear">
<a data-track-data="{"onPage":"News Article Modal","CME eligible":true}" data-track-event="Docnews Original Article View" href="http://news.doximity.com/entries/1910178?user_id=218591" target="_blank" title="http://news.doximity.com/entries/1910178?user_id=218591">View
Original Article</a></div>
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-34580447914017832442015-08-21T15:06:00.001-07:002015-08-21T15:06:30.635-07:00Drug choices for juvenile myoclonic epilepsy<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
valproic acid<br />
topiramate<br />
lamotrigine<br />
levetiracetam<br />
zonisamide<br />
<br /><br />
note these are the "broad spectrum drugs"<br />
also note: valproic acid and topiramate are teratogenic<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-14412015819634837682015-08-21T15:05:00.001-07:002015-08-21T15:05:13.004-07:00AED's and psychiatric function<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
Psychiatric function worse:<br />
<br /><br />
levetiracetam<br />
topiramate<br />
zonisamide<br />
tiagabine<br />
phenobarbital<br />
periampanel<br />
<br /><br />
psychiatric function better<br />
<br /><br />
carbamazepine<br />
valproic acid<br />
lamotrigine<br />
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script>pregabalin</div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-43602905996365319002015-08-21T15:03:00.000-07:002015-08-21T15:03:40.857-07:00AED's compared head to head to standard therapy eg. carbamazepine<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
note this is a test done by EU>> FDA<br />
<br /><br />
favorably compare: <br />
<br /><br />
oxcarbazepine<br />
eslicarbazepine<br />
lamotrigine<br />
gabapentin<br />
topiramate<br />
levetiracetam<br />
zonisamide<br />
<br /><br />
unfavorably compare (are inferior)<br />
<br /><br />
pregabalin<br />
vigabatrin<br />
<br /><br />
test not done<br />
<br /><br />
tiagabine<br />
lacosamide<br />
ezogabine<br />
perampanel<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-40540139481968468062015-08-21T15:01:00.001-07:002015-08-21T15:01:15.085-07:00Enzyme inducers-- pearls<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
enzyme inducers adverse effects (partial) include<br />
<br /><br />
1. decrease efficacy of oral contraception<br />
2. osteomalacia<br />
3. halve dose of many drugs, rendering them ineffective; this includes chemotherapeutic agents for children having CLL who have greater mortality on these drugs<br />
4. increase cholesterol<br />
5. Decrease testicular size<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-70595383430502224482015-08-21T14:58:00.000-07:002015-08-21T14:58:01.845-07:00Narrow and broad spectrum antiepileptic drugs<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
Narrow spectrum<br />
<br /><br />
carbamazepine<br />
oxcarbazepine<br />
tiagabine<br />
gabapentin<br />
pregabalin<br />
<br /><br />
Broad spectrum<br />
<br /><br />
valproic acid<br />
topiramate<br />
lamotrigine<br />
levetiracetam<br />
zonisamide<br />
parampanel<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-88089764661556127692015-08-21T14:53:00.001-07:002015-08-21T14:56:05.001-07:00New Epilepsy classification<div dir="ltr" style="text-align: left;" trbidi="on">
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
I Genetic<br />
II Focal<br />
a. Aware<br />
b Unaware<br />
III Mixed<br />
IV Unknown<br />
V Secondary generalized<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-3639768-12");
pageTracker._initData();
pageTracker._trackPageview();
</script></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-30837446.post-21139705049414190362015-04-18T16:32:00.001-07:002015-04-18T16:32:05.226-07:00IV valproate inferior for acute migraine<FONT id=role_document color=#000000 size=2 face=Arial> <DIV>Friedman BW, Garber L, Yoon A, et al. Randomized trial of iv valproate vs.metoclopramide v. ketorolac for acute migraine. Neurology 2014; 82:976-983.</DIV> <DIV> </DIV> <DIV>Authors randomized 330 patients in ER to get 1000 mg, 10 mg, or 30 mg of respective drugs above over an iv drip over 15 minutes in a double blind trial. On the primary measure of pain relief, valproate lost big to the other two drugs. On secondary measures of needing a rescue medication, iv valproate also lost.</DIV> <DIV> </DIV> <DIV>Comment-- great to have this knowledge but the two winning drugs each had relatively low sustained headache relief, 4 v. 11 v. 16 % with respective drugs above. Also metoclopramide made people feel restless.</DIV></FONT>Unknownnoreply@blogger.com0